Report: Contrave (Bupropion/Naltrexone) Expected to Become Most Widely Used Obesity Treatment
Weight-loss drug market will grow to $2.5 billion in 2022 (November 6)
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that emerging weight-loss agents will experience steady uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe, and well-tolerated drugs for this indication.
According to the new report, Contrave (bupropion/naltrexone, Orexigen/Takeda) will become the most widely used emerging therapy because it offers the best available balance of efficacy and safety among the competing therapeutic entities. The report also notes that a 3-mg formulation of Victoza (liraglutide, Novo Nordisk) will become the sales leader over the 2012–2022 forecast period owing to its premium price combined with physician familiarity and the additional metabolic benefits that the drug provides.
Further, the report finds that the U.S. launches of Qsymia (phentermine/topiramate, Vivus) and Belviq (lorcaserin, Arena Pharmaceuticals/Eisai) in 2012 and 2013, respectively, have both been met with modest uptake, suggesting that historical safety issues associated with antiobesity agents still weigh on the minds of physicians.
The report forecasts that the obesity drug market will grow more than fivefold over the next decade to exceed $2.5 billion in 2022 in the U.S., Europe, and Japan; market growth in the U.S. will be the predominant driver, overall. New agents that are expected to launch over the next decade are predicted to capture 91% of the obesity market in 2022.
“There is a great unmet need in the obesity market for agents that can induce satisfactory weight loss; a safe and well-tolerated treatment filling the void between the efficacy offered by surgery and that offered by diet, exercise, and behavioral modifications has not yet emerged,” said analyst Tim Blackstock, MB, ChB.
Source: Decision Resources; November 6, 2013.